Slide 1: Fourth Quarter and Full Year 2022 Financial Results and Business Update
Fourth Quarter and Full Year 2022 Financial Results and Business Update March 2, 2023
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation has been prepared by argenx se (“ argenx ” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presente
Slide 3: Entering 2023 in a Position of Strength
Entering 2023 in a Position of Strength Committed to our Patients and Supporters Rooted in Science through our IIP argenx Today Building Company We Want to Work For Global VYVGART launch $401M in product revenues in first year Driving innovation mission with an entrepreneurial spirit and commitment
Slide 4: Solidifying FcRn Leadership with Deep Repertoire of Preclinical and Translational Data
Solidifying FcRn Leadership with Deep Repertoire of Preclinical and Translational Data 2022: Strengthened Efgartigimod Data Story 0 - 30 - 60 Baseline 1 2 3 4 5 6 7 8 10 Mean I gG reduction % IgG reduction (%) in all ADAPT - SC and ADAPT participants LS - Mean Platelet Count Change From Baseline (x1
Slide 5: 2022: Broadened Scope of Efgartigimod Safety Database
2022 : Broadened Scope of Efgartigimod Safety Database 1. Ulrichts P, et al. J Clin Invest . 2018;128(10):4372 - 4386. doi : 10.1172/JCI97911. Scope of Safety Database >1,300 clinical study subjects Molecular design yields unique interaction with FcRn and differentiated safety profile Post - marketi
Slide 6: 2023: Key Drivers of our Path to Profitability and 'argenx 2025'
Reach more patients with VYVGART globally Pioneer FcRn class of medicines Broaden immunology pipeline Build out innovation ecosystem commercial clinical clinical discovery 2023: Key Drivers of our Path to Profitability a nd ‘argenx 2025’
Slide 7: Pipeline Growth Driven By Immunology Innovation Program
ANTIBODY ENGINEERING CLINICAL DEVELOPMENT FIRST IN CLASS | UNIQUE DESIGN | MULTIPLE INDICATIONS Efgartigimod ARGX - 119 ARGX - 117 Internal Value Creation Strategy LEADING TRANSLATIONAL BIOLOGY LABS External Value Creation Strategy OncoVerity ( Cusatuzumab ) LEO (ARGX - 112) ARGX - 109 AbbVie (ARGX
Slide 8: Positioned for a Catalyst-Rich 2023
Positioned for a Catalyst - Rich 2023 VYVGART gMG Approval in China VYVGART gMG Approval in Canada VYVGART gMG Launch in France, UK, Italy SC efgartigimod gMG Approval in US SC efgartigimod gMG Approval in EU SC efgartigimod gMG Submission in Japan VYVGART ITP Submission in Japan 2Q 2023 2H 2023 2H
Slide 9: Quarterly Product Sales
Quarterly Product Sales 2022 Vyvgart Net Sales (in millions of $) Q1 Q2 Q3 Q4 FY 22 US 21.2 73.2 124.1 159.1 377.6 Japan - 1.5 6. 0 8.3 15.8 Europe - - 0.6 5.1 5.7 Other* - 0.1 0.6 0.9 1 . 6 Total 21.2 74.8 131. 3 173.4 400 . 7 Full Year revenue of $401M in first year of launch * The product net sa
Slide 10: Fourth Quarter 2022 Financial Results
Three months ended Twelve months ended December 31 December 31 (in millions of $) 2022 2021 2022 2021 Product net sales 173 . 4 - 400 . 7 - Collaboration revenue and other 8.7 33.7 44 . 6 539.4 Total operating income 1 82 . 1 33.7 445 . 3 539.4 Cost of sales (12 . 8) - (29 . 4) - R&D expenses (147 .
Slide 11: 2022: Transformed into an Integrated Immunology Company
2022: Transformed into an Integrated Immunology Company VYVGART launched in U.S., Japan & Germany Enabled appropriate access through value - based agreements 90% US POLICIES FAVORABLE Built scalable global supply chain LARGE SCALE CAPACITY TO HANDLE DEMAND Rapid HCP adoption 90% of KEY TARGETS REACH
Slide 12: Reach More Patients with VYVGART Globally
Reach More Patients with VYVGART Globally Geographic expansion Launch SC product offering Drive usage in earlier line patients Reach more patients with VYVGART globally commercial File for ITP in Japan Ongoing studies in new indications DRIVE GROWTH IN NEW PATIENT SEGMENTS DRIVE MULTI - DIMENSIONAL
Slide 13: Our mission continues…
Our mission continues… Humility Innovation Excellence Co - Creation Empowerment
Slide 14: argenx 2025: A Leading, Sustainable Immunology Company
Lead with Compassion for our Patients Drive Impact Through Innovation Pioneer with Our Science Build the Company We Want to Work For argenx 2025: A Leading, Sustainable Immunology Company …and gMG is just the beginning